In addition to glycemic control and weight loss, certain GLP-1 receptor agonists have FDA-approved indications to lower the risk for major adverse cardiovascular events, address moderate to severe obstructive sleep apnea, and, most recently, reduce the risk for worsening kidney disease, kidney failure, and cardiovascular death
Furthermore, the STEP-TEENS trial demonstrated semaglutides effectiveness in reducing BMI and cardiometabolic risks in obese adolescents, suggesting its potential for use in younger populations (40)
Stenberg D, Litonius E, Halldner L, Johansson B, Fredholm BB, Porkka-Heiskanen T (2003) Sleep and its homeostatic regulation in mice lacking the adenosine A1 receptor
Liu Y, Luo J, Chen X, Liu W, Chen T
In the methionine cycle, methionine receives adenosine from ATP, which then creates SAM-e (s-adenosyl-methionine)